Join our webinar for a data-driven review of CRL events (2022–2025) and how PAIs, Form 483s, and inspection timing intersect to drive approval risk. Our experts go beyond public FDA data to reveal patterns sponsors & CMOs can’t afford to miss. 👉 Register here: redica.com/resource/webinar-… #CRL #FDA #PAI #Form483 #Regulator

2025 saw significant regulatory shifts. 2026 is gearing up to be just as fast-paced. 📈 Explore the most important changes in 2025 so you know what to expect in 2026 in this free webinar for regulatory and quality professionals. Save your seat 👉 redica.com/resource/webinar-…

Where does the FDA focus during PAIs, and which risks delay approval? Our latest report analyzes FDA inspection trends (2020–Q3 2025) and includes industry perspective from Sr. Director of Audits and Inspection Management at Gilead Sciences. 👉 Get the report: redica.com/resource/report-s… #PAI #FDA

How you measure supplier risk matters. We’ve taken Redica’s trusted Site Risk Scores to the next level: ✔️ Better benchmarking ✔️ Richer visuals ✔️ Integrated with Spaces Redica AI Get a clearer, faster, more actionable view of supplier performance all in one unified experience. Not a Redica user yet? See risk clearly. Act confidently. Request a demo 👉 redica.com/request-a-demo/

Traditional AI answers questions. Agentic AI solves problems. Discover how Redica AI transforms data into smarter decisions for inspection readiness, supplier management, and compliance analytics. 📚 Read the full white paper: redica.com/resource/white-pa… #RedicaAI #AI #LifeSciences #Quality #Regulatory #Compliance #Innovation

For-cause inspections are rising. 📈 So far in 2025, almost 25% of FDA inspections are for-cause, meaning sites in your supply chain are 2.5x more likely to face one. Understand the triggers and how to stay proactive in our new article. 👉redica.com/fda-increased-for…

Your next Pre-Approval Inspection doesn’t have to be a guessing game. Join experts from @GileadSciences and Redica Systems for a data-driven look at how manufacturers and sponsors can prepare effectively for PAIs. 🎟️ Save your seat: redica.com/resource/webinar-… #PAI #LifeSciences

Non-sterile ≠ low risk A recent FDA 483 shows how gaps in microbial control can expose serious compliance risks, even outside sterile operations. Read the full breakdown and access the 483 👉 redica.com/non-sterile-doesn… #FDA #Quality #Compliance #LifeSciences

🛡️ The FDA plays a critical role in protecting patients and ensuring drug quality across the industry. But what could happen if its resources are stretched too thin? #FDA #GMP hubs.la/Q03g0G9z0

[NEW BLOG POST] When a Health Canada 🇨🇦 inspector shows up at your drug manufacturing facility, what are the probable inspection targets? What areas are likely to be focused on, and what are their expectations? How does Health Canada differ from FDA is these respects? hubs.la/Q036RTNt0

A recent analysis of our data found that out of 72 inspected sites that had received warning letters, 59 (82%) had been cited for CAPA, and many also struggled with related areas like complaint handling and nonconforming product controls. In this guest post, Jackie Torfin from QLeaR Advisors shares some actionable advice on how to improve your CAPA: hubs.la/Q034pV990

During a March 2024 inspection of a finished drug company in China, FDA investigators Brandy N. Lepage and Karen A. Briggs encountered company management that limited access to manufacturing areas, disallowed photography, and supplied fewer documents than requested, many of them heavily redacted. The Redica Systems model identified 19 major deficiencies and two minor ones across four quality systems from a five-item, four-page 483. While this analysis of the 483 paints a picture of a company with major issues across four quality systems, viewed in isolation, it would not seem to solidly predict a warning letter, especially since no critical deficiencies were identified. However, as shown by the additional detail in the warning letter, the 483 does not tell the entire story of the inspection, a valuable lesson for those who analyze inspection documents. hubs.la/Q034nGXC0

Quality Assurance professionals at life sciences companies have a challenging time gathering and structuring the data they need for analysis. ❌ There are too many sources and too many different structures. ✅ Now you can get it all from one place, neatly structured so that you can spend your time on high-value analysis rather than data hunting and wrangling. Reach out to us if you'd like to see a demo customized to your company. Our team is ready to help you move to proactive inspection readiness rather than reactive.

Have thoughts on a topic in life sciences quality and regulatory compliance? Get your name out there via the Redica Systems blog! We welcome guest posts, like those from past contributors @StephanieG_PAI, @JerryChapmanGXP, and others. Also, if you don't already subscribe to The Signal, hit that blue subscribe button so you don't miss out on our 2x monthly newsletter: hubs.la/Q032RP690

This Mylan 483 from May 2024 was our most popular single document in December: redica.com/document-store/do…

Happy new year! Meet our team @SQAHeadquarters Annual in Orlando in April - we'll be at booth 214. #qualityassurance #pharma

Redica Systems is proud to complete its SOC 2 examination with the guidance of third-party audit firm @aligncompliance! This globally recognized attestation validates our commitment to critical security standards to protect and secure client data.  hubs.la/Q030d_9F0